A 40 percent reduction in dietary caloric intake increases mitochondrial calcium retention in situations where intracellular calcium levels are pathologically high. In the brain, this can help avoid the death of neurons that is associated with Alzheimer's disease, Parkinson's disease, epilepsy and stroke, among other neurodegenerative conditions.
A national science publication has featured the work of San Antonio scientists aiming to develop a more effective method for delivering neural stem cells to the brain in an effort to move forward stem cell therapies to treat neurological disorders.
Too often overlooked is the risk of depression in caregivers of patients with dementia, and a new study focuses on how depressive symptoms may differ depending on the familial relationship between caregiver and patient. The study shows how patients' behavioral symptoms are predictive of depression to different extents when the caregiver is the patient's daughter versus daughter-in-law, as reported in Journal of Women's Health.
Alzheimer's and Parkinson's diseases are different neurodegenerative conditions that can sometimes affect the same person, which has led scientists to investigate possible links between the two. Now one team, reporting in the journal ACS Chemical Neuroscience, has identified how amyloid beta, the protein fragment strongly associated with Alzheimer's disease, can induce cellular changes that might lead to Parkinson's.
Using real-time intraoperative magnetic resonance imaging (RT-IMRI) to guide transplantation of induced pluripotent stem cell (iPSC)-derived neurons (stem cells generated directly from adult cells) into the brains of non-human primates modeled with Parkinson's disease, researchers found that RT-IMRI guidance allows for better visualization and monitoring of the procedure, helps cell survival, can prevent clogging during cell delivery, and also prevents exposure to air during the procedure, all adding to the procedure's efficacy and safety.
CVT-301 is an investigational agent being developed as a self-administered, inhaled levodopa therapy for the treatment of OFF periods in Parkinson's disease. Clinical and preclinical data are presented in Science Translational Medicine.
Researchers at Johns Hopkins report they have identified a protein that enables a toxic natural aggregate to spread from cell to cell in a mammal's brain -- and a way to block that protein's action. Their study in mice and cultured cells suggests that an immunotherapy already in clinical trials as a cancer therapy should also be tested as a way to slow the progress of Parkinson's disease, the researchers say.
Engineers at The University of Texas at Austin have developed the first large-scale in vivo drug discovery platform using C. elegans (roundworms) that could speed up scientific research and more accurately assess the effectiveness of new drugs in the treatment of neurodegenerative diseases, including Parkinson's and Huntington's disease.
Twenty years ago, tumor necrosis factor (TNF) seemed a promising target in the treatment of brain diseases like multiple sclerosis or Alzheimer's Disease. But clinical trials produced disappointing results. Now University of Groningen scientists and a group of European colleagues have made an important discovery that explains the failure of these trials, and points the way to promising new treatments. The results were published on Oct. 10 in Proceedings of the National Academy of Sciences.
A protein found within the powerhouse of a cell could be the key to holding back the march of time, research by scientists at The University of Nottingham has shown.